Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
Data show bioprosthetic surgical aortic valves featuring the RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance.